Alzheimer’s Disease Therapeutics: Alternatives to Amyloid 2021
Deadline Oct 15 2021 11:59 PM (EDT)
Description

Event Date: December 3, 2021
Deadline to Submit Abstracts: October 15, 2021

This application is for a virtual Poster Presentation. Poster submissions may also be considered for Short Talks. See here for submission guidelines.

Alzheimer’s disease (AD) continues to be on the rise in the US and worldwide. Currently, more than six million Americans suffer AD while Alzheimer’s and dementia deaths have increased 16 % during the COVID-19 pandemic. Despite this, developing effective therapeutics has proven to be challenging and with the FDA’s recent delay of Aducanumab’s approval process, there are still no approved disease-modifying therapeutics for this devastating neurodegenerative disorder. The results from targeting amyloid as a disease driver —which at best can be viewed as mixed, and at worst as disappointing— highlight the importance of identifying alternative drug targets. In addition, there is great need for developing new tools for early detection and prediction of disease onset. This one-day symposium will feature the latest research on topics including neurogenesis, neuroprotection, lifestyle factors, and brain-peripheral organ interaction, with an emphasis on showcasing promising avenues for therapeutic development in AD.

To register for this event, please visit the main website at: www.nyas.org/alzalt21

Alzheimer’s Disease Therapeutics: Alternatives to Amyloid 2021


Event Date: December 3, 2021
Deadline to Submit Abstracts: October 15, 2021

This application is for a virtual Poster Presentation. Poster submissions may also be considered for Short Talks. See here for submission guidelines.

Alzheimer’s disease (AD) continues to be on the rise in the US and worldwide. Currently, more than six million Americans suffer AD while Alzheimer’s and dementia deaths have increased 16 % during the COVID-19 pandemic. Despite this, developing effective therapeutics has proven to be challenging and with the FDA’s recent delay of Aducanumab’s approval process, there are still no approved disease-modifying therapeutics for this devastating neurodegenerative disorder. The results from targeting amyloid as a disease driver —which at best can be viewed as mixed, and at worst as disappointing— highlight the importance of identifying alternative drug targets. In addition, there is great need for developing new tools for early detection and prediction of disease onset. This one-day symposium will feature the latest research on topics including neurogenesis, neuroprotection, lifestyle factors, and brain-peripheral organ interaction, with an emphasis on showcasing promising avenues for therapeutic development in AD.

To register for this event, please visit the main website at: www.nyas.org/alzalt21

Deadline
Oct 15 2021 11:59 PM (EDT)